Literature DB >> 30511907

Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry.

Ur Metser1, Anca Prica1, David C Hodgson1, Mindaugas Mozuraitis1, Maria Eberg1, Victor Mak1, Bo Green1, Amit Singnurkar1, Jill Dudebout1, Pamela MacCrostie1, Noam Tau1, Nicole Mittmann1, Deanna L Langer1.   

Abstract

Purpose To determine the relationship of PET/CT staging to the management and outcomes of participants with apparent limited-stage (LS) Hodgkin lymphoma (HL) or aggressive non-HL (ANHL) treated with curative intent. Materials and Methods This prospective multicenter registry included 850 participants (467 men and 383 women; median age, 54.1 years) from nine centers who had LS HL or ANHL on the basis of clinical data and CT, or with equivocal CT for advanced stage, who were considered for curative-intent first-line therapy. Participants were recruited between May 1, 2013, and December 31, 2015. Pre-PET/CT treatment plan was compared with treatment provided. Survival and second-line therapy initiation were compared with an historical control pool staged by using CT alone. Administrative data sources were used to control for baseline characteristics. Outcomes were assessed by using adjusted Cox proportional hazards regression and propensity score matching. Results PET/CT helped to upstage 150 of 850 participants (17.6%). There was a change in planned therapy in 224 of 580 (38.6%) of participants after PET/CT. There was a lower 1-year mortality for participants with ANHL in the PET/CT versus CT cohort (hazard ratio, 0.63; 95% confidence interval: 0.40, 1.0; P < .05) and for those with LS at PET/CT compared with those with LS at CT (hazard ratio, 0.40; 95% confidence interval: 0.21, 0.74; P = .004). For participants with HL, no 1-year outcome difference was found (P = .16). Conclusion PET/CT helped to upstage approximately 18% of participants and planned management was frequently altered. Participants with aggressive non-Hodgkin lymphoma whose first-line therapy was guided by PET/CT had significantly better survival compared with participants whose treatment was guided by CT. © RSNA, 2018 Online supplemental material is available for this article. See also the editorial by Scott in this issue.

Entities:  

Mesh:

Year:  2018        PMID: 30511907     DOI: 10.1148/radiol.2018181519

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

Review 1.  Current Role of Functional Imaging in the Management of Lymphoma.

Authors:  Bruce D Cheson; Michel Meignan
Journal:  Curr Oncol Rep       Date:  2021-11-04       Impact factor: 5.075

2.  The influence of 18F-fluorodeoxyglucose positron emission tomography/computed tomography on the N- and M-staging and subsequent clinical management of intrahepatic cholangiocarcinoma.

Authors:  Youpei Lin; Huanhuan Chong; Guohe Song; Chenhao Zhang; Liangqing Dong; Ling Aye; Fei Liang; Shuaixi Yang; Mengsu Zeng; Guangyu Ding; Shu Zhang; Jieyi Shi; Aiwu Ke; Xiaoying Wang; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

3.  Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.

Authors:  N George Mikhaeel; Martijn W Heymans; Jakoba J Eertink; Henrica C W de Vet; Ronald Boellaard; Ulrich Dührsen; Luca Ceriani; Christine Schmitz; Sanne E Wiegers; Andreas Hüttmann; Pieternella J Lugtenburg; Emanuele Zucca; Gerben J C Zwezerijnen; Otto S Hoekstra; Josée M Zijlstra; Sally F Barrington
Journal:  J Clin Oncol       Date:  2022-03-31       Impact factor: 50.717

4.  18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the diagnosis and follow-up of primary hepatic diffuse large B-cell Lymphoma: A clinical case report.

Authors:  Li Wang; Ping Dong; Weiming Hu; Bole Tian
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.